May 2013 | OncologyLive

New Guidelines, Therapies in Spotlight at PER Congress

June 18, 2013

Discussions about new guidelines on molecular testing in patients with lung cancer and a keynote address from prominent researcher Tony S. Mok, MD, will be among the highlights of the upcoming 14th International Lung Cancer Congress.

Leading Oncologists Analyze Impact of New HER2 Research on Clinical Practice

June 11, 2013

Although recent findings suggest some patients with HER2-negative breast cancer would benefit from therapies directed against overexpression of the protein, two leading oncologists do not see an immediate impact on clinical practice as further validation is needed.

Charting the Course in Myeloma: Durie Keeps Standards, New Goals in Sight

June 10, 2013

As one of the world's top multiple myeloma physicians and researchers, Brian G.M. Durie, MD, can boil his mission down to one simple goal: saving lives. But it was two people the doctor couldn't save who have most affected his path.

Wicha Sees Potential for Significant Expansion of Anti-HER2 Therapy

May 31, 2013

Max S. Wicha, MD, is an internationally renowned research expert in the field of breast oncology. His lab was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.

SGO Calls for Broad Changes in Managing Patient Care

May 22, 2013

The SGO asserts that women with gynecologic cancers frequently receive uncoordinated, fragmented testing and treatment from multiple providers at a variety of sites, often without the involvement of a specialist or supportive services.